Les N° renvoient sur un lien Web ou une publication.
Environ 230 références de publications médicales sont ici et 22 sont consultables en intégralité (en PDF ou Word). 

[1] http://www.arcs.asso.fr/Content/genhisto.htm
[2] http://www5.who.int/cancer/download.cfm?id=0000000788
[3] http://www.ligue-cancer.asso.fr/IMG/pdf/repondre_a_vos_questions.pdf
[4] http://www.anapath.necker.fr/enseign/poly/chap8_nem.html
[5] http://www.oncoprof.net/Generale2000/g09_Chimiotherapie/g09_ct05.html
[6] http://fr.wikipedia.org/wiki/Alkyle
[7] http://www.fnclcc.fr/fr/patients/dico/definition.php?id_definition=108
[8] http://www.pharmacorama.com/Rubriques/Output/Acides_nucleiquesa2_2.php
[9] http://www.oncoprof.net/Generale2000/g09_Chimiotherapie/g09_ct08.html
[10] http://www.biam2.org/www/Cla89892.html
[11] http://www.cancer.gov/newscenter/benchmarks-vol2-issue12/page2
[12] http://www.doctissimo.fr/html/sante/principalespatho/sa_1023_radiotherapie.htm
[13] http://www.canceronet.com/public/traitements/traitement04.asp
[14] http://www.sarcomaalliance.com/master.html?ArticleId=90
[15] http://www.prevention.ch/tumeursetsarcomes.htm
[16] http://www.thedoctorsdoctor.com/diseases/soft_tissue_tumors.htm
[17] Molecular Detection of the ETV6-NTRK3 Gene Fusion Differentiates Congenital Fibrosarcoma From Other Childhood Spindle Cell Tumors. Jacqueline M. Bourgeois, M.D.; Stevan R. Knezevich, Ph.D.; Joan A. Mathers, A.R.T.; Poul H. B. Sorensen, M.D., Ph.D. http://www.thedoctorsdoctor.com/diseases/fibrosarcoma.htm
[18] Ryan J.R.. Baker L.H., Benjamin R.S. - The natural history of the metastatic synovialsarcoma. Experience of the Southwest Oncology Group. - Clin. Orthop. 1982, 164. 257-260
[19] Complete resection of synovial sarcoma of prostatic fascia, Shirakawa T, Fujisawa M, Gotoh A, Okada H, Arakawa S, Kamidono S.,2003, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12639671&dopt=Abstract
[20] Primary synovial sarcoma of the kidney: a case report with literature
review, 2001, Chen S, Bhuiya T, Liatsikos EN, Alexianu MD, Weiss GH, Kahn LB, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12574853&dopt=Abstract
[21] Synovial sarcoma of the pharynx: a case report.2002, Saydam L, Kizilay A, Kalcioglu MT, Mizrak B, Bulut F, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11816387&dopt=Abstract
[22] Musculoskeletal Oncology Unit and the Samuel Lunenfeld Research Institute, Mount Sinai Hospital and the University of Toronto, Toronto, Ont. Dec. 17, 1998., Molecular alterations in bone and soft-tissue sarcoma, Robert S. Bell, MD, MSc; Jay Wunder, MD, MSc; Irene Andrulis, PhD
[23] Novel Fluorescent Ligase Detection Reaction and Flow Cytometric Analysis of SYT-SSX Fusions in Synovial Sarcoma, Gaffney R, Chakerian A, O'Connell JX, Mathers J, Garner K, Joste N, Viswanatha DS.)
[24] Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases. Barbashina V, Benevenia J, Aviv H, Tsai J, Patterson F, Aisner S, Cohen S, Fernandes H, Skurnick J, Hameed M., 2002, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12458341&dopt=Abstract
[25] Tumeurs et pseudo tumeurs synoviales du genou, Aspects anatomopathologiques, J. Amouroux, http://www.sofarthro.com/ANNALES/Annales_1993/Tum_Amouroux.html
[26] Liposarcoma of the oral and salivary gland region: a clinicopathologic study of 18 cases with emphasis on specific sites, morphologic subtypes, and clinical outcome.Fanburg-Smith JC, Furlong MA, Childers EL.
Primary liposarcoma of the orbit: A clinicopathologic study of seven cases; Yun-Cai Cai, MD, Máirín E. McMenamin, MB, MRCPI, MRCPath
Geoff Rose, MS, FRCOphth, Charles J. Sandy, FRCOphth, Ian A. Cree, MB, PhD, FRCPath, Christopher D.M. Fletcher, MD, FRCPath
[27] http://www.fm.usj.edu.lb/hp/sem/tismou04/ppl/MPL05D.htm
[28] http://www.fm.usj.edu.lb/hp/sem/tismou04/accueil.htm ou en document Word ici (pronostic des sarcomes des tissus mous)
[29] Revue d'anatomocytopathologie de septembre octobre 1995 vol 3. N°5 édité par le groupe de recherche en immuno-pathologie (GRIP)
[30] Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues. Fanburg-Smith JC, Miettinen M. http://www.thedoctorsdoctor.com/diseases/dfsp.htm
[31] Malignant fibrous histiocytoma in children. Corpron CA, Black CT, Raney RB, Pollock RE, Lally KP, Andrassy RJ. Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA. http://pubmed.gov
[32] Frequent beta-catenin abnormalities in bone and soft-tissue tumors.Iwao K, Miyoshi Y, Nawa G, Yoshikawa H, Ochi T, Nakamura Y.http://pubmed.gov
[33] Malignant fibrous histiocytoma: outcome and prognostic factors following conservation surgery and radiotherapy. Zagars GK, Mullen JR, Pollack A. Department of Radiotherapy, The University of Texas, M.D. Anderson Cancer Center, Houston, USA. http://www.thedoctorsdoctor.com/diseases/mfh.htm
[34] Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, Bonichon F, Collin F, Mandard AM, Contesso G. French Federation of Cancer Centers (FNCLCC) Sarcoma Group, Paris, France.http://www.thedoctorsdoctor.com/diseases/mfh.htm
[35] Alterations of the RB1 gene in dedifferentiated liposarcoma. Takahira T, Oda Y, Tamiya S, Yamamoto H, Kobayashi C, Izumi T, Ito K, Iwamoto Y, Tsuneyoshi M. Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.http://www.thedoctorsdoctor.com/diseases/liposarcoma.htm
[36] Pleomorphic Rhabdomyosarcoma in Adults: A Clinicopathologic Study of 38 Cases with Emphasis on Morphologic Variants and Recent Skeletal Muscle-Specific Markers . Mary A. Furlong, M.D., Thomas Mentzel, M.D. and Julie C. Fanburg-Smith, M.D. Department of Soft Tissue Pathology, Armed Forces Institute of Pathology (MAF, JCF-S), Washington, DC; and Dermatohistopathologisches Gemeinschaftslabor (TM), Friedrichshafen, Germany . Aussi sur http://www.thedoctorsdoctor.com/diseases/rhabdomyosarcoma.htm
[37] Pleomorphic rhabdomyosarcoma in children: Four cases in the pediatric age group. Mary A. Furlong, MD Julie C. Fanburg-Smith, MD http://www.thedoctorsdoctor.com/diseases/rhabdomyosarcoma.htm
[38] PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. Department of Pathology, Children's and Women's Hospital of British Columbia, Vancouver, British Columbia, Canada. http://www.thedoctorsdoctor.com/diseases/rhabdomyosarcoma.htm
[39] Volume 33, n°3, 2003. Tumeurs stromales gastro-intestinales P. Bedossa Le Kremlin-Bicêtre (France). http://www.acta-endoscopica.com/r330303.html
[40] http://www.gistsupport.org
[41] http://www.cregg.org/rubrique.aspx?page=256
[42] CANTIN J, McNEER GP, CHU FC, BOOTHER RJ : The problem of local recurrence after treatment of soft tissue sarcoma. Ann Surg, 1968, 168, 47-53.
[43] ENNEKING WF, SPANIER SS, MALAWER MM : The effects of the anatomic setting on the results of surgical procedure for soft part sarcoma of the thigh. Cancer, 1981, 47, 1005-22.
[44] GAYNOR JJ, TAN CC, CASPER ES et al : Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity : a study of 423 adults. J. Clin. Oncol 1992, 10, 1317-29.
[45] MANDARD AM, PETIOT JF, MARNAY J, et al : Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer 1989, 63, 1437-51.
[46] MARKHEDE G, ANGERVALL L, STENER B : A multivariate analysis of the prognosis after surgical treatment of malignant soft tissue tumors. Cancer 1982, 49, 1721-33.
[47] RAVAUD A, BUI NB, COINDRE JM, et al : Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. Br J Cancer 1992, 66, 961-9.
[48] http://www.leiomyosarcoma.info/
[49]Buck P., Mickelson M.R., Bonfiglio M., - Synovial sarcoma. A review of 33 cases. - Clin. Orthop.,1981, 156, 211-215. http://www.soo.com.fr/soo_site/p_protec/aoo30/art10.htm
[50]5. Henderson S.A.. Davis R.. Nixon J.R. - Synovial sarcoma. A clinico pathological review. - Intern. Orthop.(SICOT), 1991, 15. 251-55. http://www.soo.com.fr/soo_site/p_protec/aoo30/art10.htm
[51] Ivanov-Dutescu R., Tomeno B., Mallet F.. Laugier A.. Forest M. Synovialosarcome. Etude d'une série de 46 cas. - Rev. Chir. Orthop. 1992. 78. 1-7. http://www.soo.com.fr/soo_site/p_protec/aoo30/art10.htm
[52] Skytting BT, Bauer HC, Perfekt R, et al.: Clinical course in synovial sarcoma: a Scandinavian sarcoma group study of 104 patients. Acta Orthop Scand 70 (6): 536-42, 1999, http://www.cancer.gov/cancerinfo/pdq/treatment/child-soft-tissue-sarcoma/healthprofessional/
[53] Synovial sarcoma of the extremities.Results of surgical and multimodal therapy, Ulmer C, Kettelhack C, Tunn PU, Reichardt P, Hohenberger P, Schlag PM, 2003, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12719879&dopt=Abstract]
[54] Radiation-Associated Cutaneous Atypical Vascular Lesions and Angiosarcoma: Clinicopathologic Analysis of 42 Cases. Brenn T, Fletcher CD. From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Am J Surg Pathol. 2005 Aug;29(8):983-996. http://www.thedoctorsdoctor.com/diseases/angiosarcoma.htm
[55] Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York. Cancer 1989 Jan 1;63(1):1-13. http://www.thedoctorsdoctor.com/diseases/alveolarsoftparts.htm.
[56] Alveolar soft part sarcoma metastatic to the breast. Hanna NN, O'Donnell K, Wolfe GR. Department of Surgery, St. Elizabeth's Medical Center of Boston, Tufts University School of Medicine, Massachusetts 02135, USA Surg Oncol 1996 Feb;61(2):159-62. http://www.thedoctorsdoctor.com/diseases/alveolarsoftparts.htm.
[57] http://www.fnclcc.fr/fr/patients/dico/alpha.php#h
[58] 16. Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 1995,103: 41-47. http://www.bmlweb.org/delchier_022.htm
[59] . Emory TS, Sobin LH, Lukes L et al: Prognosis of gastrointestinal smooth muscle (stromal) tumors. Am J Surg Pathol 1999, 23: 82-87. http://www.bmlweb.org/delchier_022.htm
[60] http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=668
[61] http://www.emc-consulte.com/articleFrame.jsp?item=6809&filetype=1&cap=1&&item=6809&cap=1&filetype=1
[62] Les tumeurs osseuses. Février 2004. IGR. Anne d'Andon, Gilles Vassal, Odile Oberlin, Olivier Hartmann; http://www.igr.fr/php/index.php?ids_path=5.193.683.684
[63] Am J Surg Pathol. 2002 May. Pleomorphic Liposarcoma: Clinicopathologic, Immunohistochemical, and Follow-up Analysis of 63 Cases: A Study From the French Federation of Cancer Centers Sarcoma Group.Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, Taylor S, Chateau MC, Marques B, Picot V, Guillou L.University Institute of Pathology (S.G., L.G.), Lausanne, and Department of Pathology (S.T.), University Hospital, Geneva, Switzerland.Am J Surg Pathol 2002 May;26(5):601-16 http://pubmed.gov
[64] Am J Surg Pathol. 2004 Oct. Pleomorphic Liposarcoma: Clinicopathologic Analysis of 57 Cases. Hornick JL, Bosenberg MW, Mentzel T, McMenamin ME, Oliveira AM, Fletcher CD.Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; dagger Department of Pathology, University of Vermont, Burlington, VT; double dagger Dermatohistopathologisches Gemeinschaftslabor, Friedrichshafen, Germany; and section signDepartment of Pathology, St. James's Hospital, Dublin, Ireland.Am J Surg Pathol. 2004 Oct;28(10):1257-1267. http://pubmed.gov
[65] Le Quotidien du médecin ; 5 octobre 2004
[66] Prognostic factors in 227 patients with malignant fibrous histiocytoma.Pezzi CM, Rawlings MS Jr, Esgro JJ, Pollock RE, Romsdahl MM. Department of General Surgery, University of Texas M. D. Anderson Cancer Center, Houston 77030. Cancer 1992 Apr 15;69(8):2098-103; http://www.thedoctorsdoctor.com/diseases/mfh.htm
[67] 2001 Mar;14(3):179-84. Pleomorphic liposarcoma: a clinicopathologic analysis of 19 cases.Downes KA, Goldblum JR, Montgomery EA, Fisher C. Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. http://pubmed.gov
[68] 2004 Dec;75(12):1182-90. Liposarcoma of the extremities: recent developments in surgical therapy--analysis of 167 patients. Lehnhardt M, Kuhnen C, Drucke D, Homann HH, Joneidi Jafari H, Steinau HU. http://pubmed.gov
[69] Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):122-5. Prognostic factors and treatment of 74 patients with dermatofibro-sarcoma protuberans. Liu MZ, Wang XS, Cai L, Liu H, Chen EC, Cui NJ. http://pubmed.gov
[70] J Surg Oncol. 2001 Dec;78(4):225-31. Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group studies (1979-1995). Cecchetto G, Carli M, Alaggio R, Dall'Igna P, Bisogno G, Scarzello G, Zanetti I, Durante G, Inserra A, Siracusa F, Guglielmi M; Italian Cooperative Group. http://pubmed.gov
[71] Am J Clin Oncol. 2002 Feb;25(1):16-22. Malignant fibrous histiocytoma: a retrospective study of 109 cases. Belal A, Kandil A, Allam A, Khafaga Y, El-Husseiny G, El-Enbaby A, Memon M, Younge D, Moreau P, Gray A, Schultz H. http://pubmed.gov
[72] 1996 May 1;77(9):1823-30. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Le Doussal V, Coindre JM, Leroux A, Hacene K, Terrier P, Bui NB, Bonichon F, Collin F, Mandard AM, Contesso G. http://pubmed.gov
[73] Eur J Pediatr Surg. 2005 Dec;15(6):409-13. Clinical characteristics and the prognosis of rhabdomyosarcoma - a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. Suita S, Noguchi S, Takamatsu H, Mizote H, Nagasaki A, Inomata Y, Hara T, Okamura J, Miyazaki S, Kawakami K, Eguchi H, Tsuneyoshi M; Committee for Pediatric Solid Malignant Tumors in the Kyushu Area. http://pubmed.gov
[74] J Egypt Natl Canc Inst. 2005 Jun;17(2):67-75. Rhabdomyosarcoma in Childhood: A retrospective Analysis of 190 Patients Treated at a Single Institution. Shouman T, El-Kest I, Zaza K, Ezzat M, William H, Ezzat I. http://pubmed.gov
[75] J Pediatr Surg. 2006 Jan;41(1):187-93. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. Kayton ML, Meyers P, Wexler LH, Gerald WL, LaQuaglia MP. http://pubmed.gov
[76] Eur J Cancer. 2002 Jul;38(10):1324-8. Alveolar soft part sarcoma. a report of 15 cases. van Ruth S, van Coevorden F, Peterse JL, Kroon BB. http://pubmed.gov
[77] Ann Oncol. 2000 Nov;11(11):1445-9. Alveolar soft part sarcoma in children and adolescents: A report from the Soft-Tissue Sarcoma Italian Cooperative Group.Casanova M, Ferrari A, Bisogno G, Cecchetto G, Basso E, De Bernardi B, Indolfi P, Fossati Bellani F, Carli M. http://pubmed.gov
[78] Eur J Surg Oncol. 2004 Jun;30(5):565-72. Prognostic factors in soft tissue leiomyosarcoma of the extremities: a retrospective analysis of 42 cases. Massi D, Beltrami G, Mela MM, Pertici M, Capanna R, Franchi A. http://pubmed.gov
[79] Gynecol Oncol. 1999 Aug;74(2):196-201. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, Czerwenka K, Leodolter S, Kainz C. http://pubmed.gov
[80] Ann Surg Oncol. 1997 Apr-May;4(3):223-7. Leiomyosarcoma in childhood and adolescence. Hwang ES, Gerald W, Wollner N, Meyers P, La Quaglia MP. http://pubmed.gov
[81] Cancer. 1992 Jul 1;70(1):114-9. Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. http://pubmed.gov
[82] Cancer. 1999 Feb 1;85(3):562-82. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Makhlouf HR, Ishak KG, Goodman ZD. http://pubmed.gov
[83] Cancer J. 2005 Jul-Aug;11(4):354. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. http://pubmed.gov
[84] Br J Plast Surg. 2003 Mar;56(2):129-34. Br J Plast Surg. 2004 Mar;57(2):177-8. Angiosarcoma of the breast: a 30 year perspective with an optimistic outlook. Georgiannos SN, Sheaff M. http://pubmed.gov
[85] Mod Pathol. 2003 Mar;16(3):263-71. Oral and salivary gland angiosarcoma: a clinicopathologic study of 29 cases. Fanburg-Smith JC, Furlong MA, Childers EL. http://pubmed.gov
[86] Bull Cancer. 1992;79(1):101-12. Neurosarcoma associated with Von Recklinghausen disease: apropos of 25 cases observed at the Gustave Roussy Institute from 1967 to 1990; Aguiar Vitacca S, Sarrazin D, Henry-Amar M, Spielmann M, Genin J, Bernheim A, Contesso G. http://pubmed.gov
[87] Fédération Nationale Centre de Lutte contre le cancer et La société Française d'oncologie pédiatrique. Mars 1999. Standards, Options et Recommandation pour le diagnostic, le traitement et la surveillance de l'ostéosarcome. PDF ici.
[89] J Clin Oncol. 2006 Mar 1;24(7):1161-8. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. Petrilli AS, de Camargo B, Filho VO, Bruniera P, Brunetto AL, Jesus-Garcia R, Camargo OP, Pena W, Pericles P, Davi A, Prospero JD, Alves MT, Oliveira CR, Macedo CR, Mendes WL, Almeida MT, Borsato ML, dos Santos TM, Ortega J, Consentino E; Brazilian Osteosarcoma Treatment Group Studies III and IV. http://pubmed.gov
[90] Cancer. 2006 Mar 1;106(5):1154-61. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. http://pubmed.gov
[91] Eur J Cancer. 2005 Sep;41(14):2079-85. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, Picci P. http://pubmed.gov
[92] J Pediatr (Rio J). 2004 Jan-Feb;80(1):65-70. Clinical features in osteosarcoma and prognostic implications; Rech A, Castro CG Jr, Mattei J, Gregianin L, Di Leone L, David A, Rivero LF, Tarrago R, Abreu A, Brunetto AL. http://pubmed.gov
[93] Eur J Cancer. 2003 Mar;39(4):488-94. J Cancer. 2003 Nov;39(17):2566; author reply 2567-8. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, Stenwig AE, Willen H, Holmstrom T, Folleras G, Brosjo O, Kivioja A, Jonsson K, Monge O, Saeter G. http://pubmed.gov
[94] J Clin Oncol. 2003 May 15;21(10):2011-8. Comment in: J Clin Oncol. 2004 Dec 15;22(24):5017; author reply 5017-8. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. Kager L, Zoubek A, Potschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jurgens H, Gadner H, Bielack SS; Cooperative German-Austrian-Swiss Osteosarcoma Study Group. http://pubmed.gov
[95]Z Orthop Ihre Grenzgeb. 2002 Nov-Dec;140(6):652-5. Osteosarcoma and Ewing's sarcoma--The most frequent malignant bone tumors in children--therapy and outcome. Sluga M, Windhager R, Pfeiffer M, Ofner P, Lang S, Dominkus M, Nehrer S, Zoubek A, Kotz R. http://pubmed.gov
[96] Clin Orthop Relat Res. 1997 Dec;(345):206-14. Prognostic factors among 130 patients with osteosarcoma. Pochanugool L, Subhadharaphandou T, Dhanachai M, Hathirat P, Sangthawan D, Pirabul R, Onsanit S, Pornpipatpong N. http://pubmed.gov
[97] Zhonghua Zhong Liu Za Zhi. 2005 Oct;27(10):598-601. Multivariate analysis of prognosis in gastrointestinal stromal tumor. Bai YK, Shao YF, Shi SS, Gao YN, Sun YT, Cheng SJ, Liu XY. http://pubmed.gov
[98] Surg Oncol. 2005 Aug;14(2):75-84. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Kosmadakis N, Visvardis EE, Kartsaklis P, Tsimara M, Chatziantoniou A, Panopoulos I, Erato P, Capsambelis P. http://pubmed.gov
[99] J Oral Maxillofac Surg. 2005 Oct;63(10):1461-77. Leiomyosarcomas of the oral tissues: clinicopathologic analysis of 50 cases. Vilos GA, Rapidis AD, Lagogiannis GD, Apostolidis C. http://pubmed.gov
[100] Acta Obstet Gynecol Scand. 2003 Jan;82(1):74-81. Leiomyosarcoma of the uterus: a clinicopathologic study of 21 cases. Hsieh CH, Lin H, Huang CC, Huang EY, Chang SY, ChangChien CC. http://pubmed.gov
[101] Histopathology. 2004 Nov;45(5):526-37. Lingual alveolar soft part sarcoma; 14 cases: novel clinical and morphological observations. Fanburg-Smith JC, Miettinen M, Folpe AL, Weiss SW, Childers EL. http://pubmed.gov
[102] Med Pediatr Oncol. 1996 Feb;26(2):81-4. Ped Pediatr Oncol. 2001 Nov;37(5):482-3. Alveolar soft part sarcoma in children and adolescents: clinical features and outcome of 11 patients. Pappo AS, Parham DM, Cain A, Luo X, Bowman LC, Furman WL, Rao BN, Pratt CB. http://pubmed.gov
[103] Cancer. 2005 Jul 1;104(1):183-90. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Mazzoleni S, Bisogno G, Garaventa A, Cecchetto G, Ferrari A, Sotti G, Donfrancesco A, Madon E, Casula L, Carli M; Associazione Italiana di Ematologia e Oncologia Pediatrica Soft Tissue Sarcoma Committee. http://pubmed.gov
[104] Cancer. 2003 Aug 1;98(3):571-80. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarria P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, Casali PG. http://pubmed.gov
[105] J Clin Oncol. 2003 Jan 1;21(1):78-84. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. http://pubmed.gov
[106] Cancer Invest. 2000;18(3):223-41. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Ruymann FB, Grovas AC. http://pubmed.gov
[107] Acta Oncol. 2004;43(6):530-5. Treatment results and prognostic factors in patients with malignant fibrous histiocytoma. Hsu HC, Huang EY, Wang CJ. http://pubmed.gov
[108] Acta Orthop Scand. 1999 Aug;70(4):353-60. Malignant fibrous histiocytoma of bone: a retrospective EMSOS study of 125 cases. European Musculo-Skeletal Oncology Society. Bielack SS, Schroeders A, Fuchs N, Bacci G, Bauer HC, Mapeli S, Tomeno B, Winkler K. http://pubmed.gov
[109] Zhonghua Zhong Liu Za Zhi. 2005 Dec;27(12):727-30. Expressions and significance of E-cadherin and beta-catenin in synovial sarcoma. Sun BC, Sun Y, Zhao XL, Liu YX, Zhang SW, Liu YX. http://pubmed.gov
[110] Oncogene. 2004 Nov 11;23(53):8629-38. E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma. Saito T, Oda Y, Kawaguchi K, Sugimachi K, Yamamoto H, Tateishi N, Tanaka K, Matsuda S, Iwamoto Y, Ladanyi M, Tsuneyoshi M. http://pubmed.gov
[111] Cancer. 2004 Aug 1;101(3):627-34. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. http://pubmed.gov
[112] Am J Clin Oncol. 2004 Apr;27(2):122-7. Synovial sarcoma prognostic factors and patterns of failure. Paulino AC. http://pubmed.gov
[113] Clin Orthop Relat Res. 2004 Feb;(419):155-61. Synovial sarcoma: the importance of size and location for survival. Deshmukh R, Mankin HJ, Singer S. http://pubmed.gov
[114] J Clin Oncol. 2003 Apr 15;21(8):1602-11. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. Okcu MF, Munsell M, Treuner J, Mattke A, Pappo A, Cain A, Ferrari A, Casanova M, Ozkan A, Raney B. http://pubmed.gov
[115] Med Pediatr Oncol. 2001 Aug;37(2):90-6. Synovial sarcoma in children and adolescents: thirty three years of experience with multimodal therapy. Okcu MF, Despa S, Choroszy M, Berrak SG, Cangir A, Jaffe N, Raney RB. http://pubmed.gov
[116] J Clin Oncol. 2004 Oct 15;22(20):4040-50. Epub 2004 Sep 13. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, Somerhausen Nde S, Michels JJ, Jundt G, Vince DR, Taylor S, Genevay M, Collin F, Trassard M, Coindre JM. http://pubmed.gov
[117] Cancer Res. 2002 Jan 1;62(1):135-40. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O. http://pubmed.gov
[118] Ann Surg. 2004 Oct;240(4):686-95; discussion 695-7. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Eilber FC, Eilber FR, Eckardt J, Rosen G, Riedel E, Maki RG, Brennan MF, Singer S. http://pubmed.gov
[119] http://www.cancerindex.org/ccw/faq/ewings.htm#q5
[120] Pediatr Hematol Oncol. 2004 Oct-Nov;21(7):597-610. Treatment results and prognostic factors in Ewing sarcoma. Kutluk MT, Yalcin B, Akyuz C, Varan A, Ruacan S, Buyukpamukcu M. http://pubmed.gov
[121] J Cancer Res Clin Oncol. 2005 Apr;131(4):219-25. Epub 2004 Dec 22. Ewing's sarcoma and primitive neuroectodermal tumor of hand and forearm. Experience of the Cooperative Ewing's Sarcoma Study Group. Daecke W, Ahrens S, Juergens H, Martini AK, Ewerbeck V, Kotz R, Winkelmann W, Bernd L. http://pubmed.gov
[122] Eur J Cancer. 2004 Jan;40(1):73-83. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Bacci G, Forni C, Longhi A, Ferrari S, Donati D, De Paolis M, Barbieri E, Pignotti E, Rosito P, Versari M. http://pubmed.gov
[123] Clin Orthop Relat Res. 2004 Mar;(420):230-8. Prognostic factors in Ewing's sarcoma of the foot. Casadei R, Magnani M, Biagini R, Mercuri M. http://pubmed.gov
[124] Arch Surg. 2003 Mar;138(3):281-5. Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival?Martin RC 2nd, Brennan MF. Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. http://pubmed.gov
[125] Eur J Surg Oncol. 2001 Sep;27(6):569-73. Comment in: Eur J Surg Oncol. 2002 Dec;28(8):896. A long-term review of the treatment of patients with Ewing's sarcoma in one institution. Sluga M, Windhager R, Lang S, Heinzl H, Krepler P, Mittermayer F, Dominkus M, Zoubek A, Kotz R. http://pubmed.gov
[126] http://bonetumor.org/tumors/pages/page39.html
[127] http://www.france-cancer.org/netscope.php?i=5&titre=Sarcome+des+tissus+mous
[128] http://www.fm.usj.edu.lb/hp/sem/tismou04/accueil.htm ou version word ici (traitement des sarcomes des tissus mous)
[129] ENNEKING W.F., SPANIER S.S., MALAWER M.M., The effects of the anatomic setting on the results of surgical procedures for soft part sarcoma of the thigh. Cancer, 1981, 47, 1005-22. http://pubmed.gov
[130] Verweij J, Pinedo HM et al. Systemic treatment of advanced or metastatic soft tissue sarcoma. In Pinedo HM, Verweij J, Suit HD, eds. Soft Tissue Sarcomas : New developments in the Multidiciplinary Approach to Treatment. Boston, MA, Kluwer Academic Publishers, 1991.
[131] Oncologist. 2005 Nov-Dec;10(10):833-41. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Sleijfer S, Seynaeve C, Verweij J. PDF ici ou sur http://pubmed.gov 
[132] Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-Analysis Collaboration. Lancet 1997;350:1647–1654. http://pubmed.gov ou http://theoncologist.alphamedpress.org/cgi/content/full/10/10/833#R1
[133] Blay J-Y, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003;39:64–69.
[134] Judson I, Radford JA, Harris M et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870–877. http://pubmed.gov
[135] Nielsen OS, Dombernowsky P, Mouridsen HT et al. High-dose epirubicin is not an alternative of standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998;78:1634–1639. http://pubmed.gov
[136] Verweij J, Lee SM, Ruka W et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000;18:2081–2086. http://pubmed.gov
[137] Bramwell VH, Mouridsen HT, Santoro A et al. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization of Research and Treatment Cancer (EORTC), Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 1993;31(suppl 2):S180–S184. http://pubmed.gov
[138] Okuno S, Ryan LM, Edmonson JH et al. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797). Cancer 2003;97:1969–1973. http://pubmed.gov
[139] vancárová L, Blay JY, Judson IR et al. Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38:556–559. http://pubmed.gov
[140 ] Balcerzak SP, Benedetti J, Weiss GR et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a Southwest Oncology Group study. Cancer 1995;76:2248–2252. http://pubmed.gov
[141] Gian VG, Johnson TJ, Marsch RW et al. A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue or bone sarcomas. J Exp Ther Oncol 1996;1:186–190.http://pubmed.gov
[142] Woll PJ, Judson I, Lee SM et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1999;35:410–412. http://pubmed.gov
[143] Muss HB, Bundy BN, Adcock L et al. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990;13:32–34. http://pubmed.gov
[144] Brennan MF, Alektiar KM, Maki RG. Soft tissue sarcoma. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 6th Ed. Philadelphia: Lippincott Williams & Wilkins 2001:1841–1891. http://pubmed.gov
[145] Budd GT, Rankin C, Hutchins LF et al. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Invest New Drugs 2002;20:129–132. http://pubmed.gov
[146] Chang P, Wiernik PH. Combination chemotherapy with doxorubicin and streptozocin. I. Clinical results in patients with advanced sarcoma. Clin Pharmacol Ther 1976;20:605–610. http://pubmed.gov
[147] Schoenfeld DA, Rosenbaum C, Horon J et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycine-D and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757–2762. http://pubmed.gov
[148] Muss HB, Bundy B, DiSaia J et al. Treatment of recurrent or advanced uterine sarcoma: A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648–1653. http://pubmed.gov
[149] Borden EC, Amato DA, Edmonson JH et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft tissue sarcomas. Cancer 1990;66:862–867. http://pubmed.gov
[150] Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269–1275. http://pubmed.gov
[151] Santoro A, Tursz T, Mouridsen HT et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma: a randomized study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537–1545. http://pubmed.gov
[152] Santoro A, Tursz T, Mouridsen HT et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma: a randomized study of the European Organization of Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537–1545. http://pubmed.gov
[153] Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcoma. J Clin Oncol 1987;5:840–850. http://pubmed.gov
[154] Nielsen OS, Dombernowsky P, Mouridsen HT et al. High-dose epirubicin is not an alternative of standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 1998;78:1634–1639. http://pubmed.gov
[155] Jelic S, Kovcin V, Milanovic N et al. Randomized study of high-dose epirubicin versus high-dose epirubicin and cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer 1997;33:220–225. http://pubmed.gov
[156] Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276–1285. http://pubmed.gov
[157] Baker LH, Frank J, Fine G et al. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin-D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III Southwest Oncology Group Study (7613). J Clin Oncol 1987;5:851–861. http://pubmed.gov
[158] 14- Le Cesne A. Chimiothérapie des sarcomes des tissus mous métastatiques. Presse Med. 1995 Sep 16;24(26):1214-20. Review. French. ou http://www.france-cancer.org/netscope.php?i=5&titre=Sarcome+des+tissus+mous
[159] Int J Clin Oncol. 2005 Apr;10(2):81-5. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes. Kondo H, Okumura T, Ohde Y, Nakagawa K. http://pubmed.gov
[160] Gan To Kagaku Ryoho. 2004 Sep;31(9):1319-23. Pulmonary metastasectomy for osteosarcomas and soft tissue sarcomas. Kimura H, Suzuki M, Ando S, Iida T, Iwata T, Tatesaki S, Isii T, Yonemoto T. http://pubmed.gov
[161] Curr Treat Options Oncol. 2002 Dec;3(6):497-505. Metastasectomy for limited metastases from soft tissue sarcoma. Abdalla EK, Pisters PW. http://pubmed.gov
[162] Semin Thorac Cardiovasc Surg. 2002 Jan;14(1):35-44. The role of pulmonary metastasectomy in soft tissue sarcoma.Temple LK, Brennan MF. http://pubmed.gov
[163] Acta Chir Belg. 2001 Nov-Dec;101(6):267-72. Long-term results of surgical resection of lung metastases. Hendriks JM, Romijn S, Van Putte B, Eyskens E, Vermorken JB, Van Marck E, Van Schil PE. http://pubmed.gov
[164] Oncology (Williston Park). 2000 Jun;14(6):835-41; discussion 842-4, 847. Surgical treatment of metastatic pulmonary soft-tissue sarcoma. Chao C, Goldberg M. http://pubmed.gov
[165] La chirurgie de reconstruction par greffe osseuse en PDF, Institut Curie
[166] Ann Surg Oncol. 2004 Jul;11(7):714-9. Prognosis of lymph node metastasis in soft tissue sarcoma. Behranwala KA, A'Hern R, Omar AM, Thomas JM. http://pubmed.gov
[167] Clin Orthop Relat Res. 2004 Sep;(426):129-34. Lymph node metastasis in soft tissue sarcoma in an extremity. Riad S, Griffin AM, Liberman B, Blackstein ME, Catton CN, Kandel RA, O'Sullivan B, White LM, Bell RS, Ferguson PC, Wunder JS. http://pubmed.gov
[168] Heart Lung Circ. 2004 Dec;13(4):374-8. Hand-assisted Thoracoscopic Surgery causes less postoperative pain than limited thoracotomy after cessation of epidural analgesia. Paiva JM, Wright GM. http://pubmed.gov
[169] An Sist Sanit Navar. 2005;28 Suppl 3:93-102. Medium and long-term results of the use of videothorascopy in surgery of pulmonary metastasis resection. Torre W, Rodriguez-Spiteri N, Villalobos W, Gurpide A, Fernandez O, Lopez-Picazo J. http://pubmed.gov
[170] : Eur J Surg Oncol. 2002 Dec;28(8):864-8. Long term survival of thoracoscopic metastasectomy vs metastasectomy by thoracotomy in patients with a solitary pulmonary lesion. Mutsaerts EL, Zoetmulder FA, Meijer S, Baas P, Hart AA, Rutgers EJ. http://pubmed.gov
[171] Ann Thorac Surg. 2001 Jul;72(1):230-3. Outcome of thoracoscopic pulmonary metastasectomy evaluated by confirmatory thoracotomy. Mutsaerts EL, Zoetmulder FA, Meijer S, Baas P, Hart AA, Rutgers EJ. http://pubmed.gov
[172] Lasers Surg Med. 2006 Feb 8; Limited lung resection using the potassium-titanyl-phosphate laser. Nagayasu T, Matsumoto K, Morino S, Tagawa T, Nakamura A, Abo T, Yamasaki N, Hayashi T. http://pubmed.gov
[173] Lasers Surg Med. 2006 Jan;38(1):26-32. Laser resection technique and results of multiple lung metastasectomies using a new 1,318 nm Nd:YAG laser system. Rolle A, Pereszlenyi A, Koch R, Bis B, Baier B. http://pubmed.gov
[174] Rocz Akad Med Bialymst. 2005;50:193-6. Laser resection of lung parenchyma--a new technical and clinical approach. Rolle A, Kozlowski M. http://pubmed.gov
[175] Ann Thorac Surg. 2002 Sep;74(3):865-9. Lobe-sparing resection of multiple pulmonary metastases with a new 1318-nm Nd:YAG laser--first 100 patients. Rolle A, Koch R, Alpard SK, Zwischenberger JB. http://pubmed.gov
[176] Radiologe. 2004 Apr;44(4):370-5. RFA of bone and soft tissue tumors. Jakobs TF, Hoffmann RT, Vick C, Wallnofer A, Reiser MF, Helmberger TK. http://pubmed.gov
[177] Respiration. 2006;73(2):250-2. Epub 2005 Jul 21. Radiofrequency thermal ablation of primary pleural synovial sarcoma. Lee HK, Kwon HJ, Lee HB, Jin GY, Chung MJ, Lee YC. http://pubmed.gov
[178] http://www.ametist.org/cancer_la_chirurgie_exerese.php
[179] Fata F, O’Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034–2037. http://pubmed.gov
[180] Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052–1056. http://pubmed.gov
[181] http://www.novartisoncology.com/page/gist_fr.jsp
[182] Nielsen OS, West RB, Linn SC et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301–1307. http://pubmed.gov
[183] Crit Rev Oncol Hematol. 2006 Mar 10. New emerging drugs in soft tissue sarcoma. Milano A, Apice G, Ferrari E, Fazioli F, de Rosa V, de Luna AS, Iaffaioli RV, Caponigro F. http://pubmed.gov
[184] J Clin Oncol. 2005 Jan 20;23(3):576-84. J Clin Oncol. 2005 Aug 1;23(22):5276. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. PDF ici ou http://pubmed.gov
[185] Int J Cancer. 2006 Feb 22. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis.Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Blay JY. http://pubmed.gov
[186] Cancer. 2006 Feb 1;106(3):703-7. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G, Provenzi M, Bertolini P, Paolucci P, Carli M. http://pubmed.gov
[187] Cancer. 2005 Oct 15;104(8):1706-12. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J; Spanish Group for Research on Sarcomas. http://pubmed.gov
[188] 1: Cancer. 2005 Apr 1;103(7):1431-8. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK. http://pubmed.gov
[189] http://www.novartis.fr/a_public/a04_qui_sommes_nous/a04_04_rd/a04_04_07_03_essais_cliniques.shtml
[190] Invest New Drugs. 2006 Mar 9; A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E. http://pubmed.gov
[191] Am J Clin Oncol. 2006 Feb;29(1):59-61. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A. http://pubmed.gov
[192] Standards, Options et Recommandations 2002 sur les antalgiques des douleurs cancéreuses, version PDF ici
[193] http://www.institut-upsa-douleur.org/patients/douleur_chronique/cancer/douleur_cancer_02.htm
[194] http://psydoc-fr.broca.inserm.fr/toxicomanies/toxicomanie/produits/opiaces/index.htm
[195] JO de la République Française. 19 août 2004. Texte 31 sur 87.
[196] http://www.oncoprof.net/Generale2000/g09_Chimiotherapie/g09_ct19.html#Pouvoir
[197] Pharmacol Biochem Behav. 2005 Jan;80(1):35-44. Epub 2004 Dec 8. Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva).Darmani NA, Crim JL.Department of Pharmacology, Kirksville College of Osteopathic Medicine, A.T. Still University of Health Sciences, 800 West Jefferson, Kirksville, MO 63501, USA. http://pubmed.gov
[198] Brain. 2003 Jun;126(Pt 6):1252-70. Cannabis and the brain. Iversen L. Department of Pharmacology, University of Oxford, Oxford, UK. les.iverson@pharm.ox.ac.uk. http://pubmed.gov
[199] Med Hypotheses. 2006;66(2):234-46. Epub 2005 Oct 4. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.Russo E, Guy GW. http://pubmed.gov
[200] Marinol : version PDF
[201] Neuroreport. 2002 Apr 16;13(5):567-70. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. http://pubmed.gov
[202] Pharmacol Biochem Behav. 2001 Jul-Aug;69(3-4):343-50. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac.Soderpalm AH, Schuster A, de Wit H. Department of Psychiatry, The University of Chicago. http://pubmed.gov
[203] Neuropsychopharmacology. 2001 Feb;24(2):198-203. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. http://pubmed.gov
[204] Clin Pract Epidemol Ment Health. 2006 Mar 23;2(1). Substance abuse in first-episode schizophrenic patients: a retrospective study. Mauri MC, Volonteri LS, De Gaspari IF, Colasanti AA, Brambilla MA, Cerruti LL. http://pubmed.gov
[205] 1: Br J Psychiatry. 2006 Mar;188:237-42. Comorbid substance use and age at onset of schizophrenia. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Department of Psychological Medicine, Imperial College Faculty of Medicine, Charing Cross Campus, St Dunstan's Road, London. http://pubmed.gov
[206] Methods Mol Med. 2006;123:235-53. Methods for clinical research involving cannabis administration. Gorelick DA, Heishman SJ. Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA. http://pubmed.gov
[207] 1: Br J Psychiatry. 2005 Dec;187:510-5. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. http://pubmed.gov
[208] Drug Alcohol Rev. 1998 Dec;17(4):433-44. Cannabis use and psychosis.Hall W.National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 2052, Australia. http://pubmed.gov
[209] Eur Psychiatry. 2005 Jun;20(4):349-53. Cannabis use and outcome of recent onset psychosis. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Department of Psychiatry, Mount Carmel Hospital. http://pubmed.gov
[210] Addiction. 2005 May;100(5):612-8. Cannabis use predicts future psychotic symptoms, and vice versa. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. http://pubmed.gov
[211] Cannabis : Quels effets sur le comportement et la santé ? 2001. Inserm. 
[212] Dialogues Clin Neurosci. 2005;7(1):81-5. Interpreting the association between cannabis use and increased risk for schizophrenia.Weiser M, Noy S. Department of Psychiatry, Sheba Medical Center, Tel-Hashomer, Israel. http://pubmed.gov
[213] http://www.pharmacorama.com/Rubriques/Output/Adrenergiques5.php
[215] Fédération Nationale des Centres de Lutte contre le Cancer : standards, options et recommandations pour l'utilisation des antiémitiques en cancérologie. 1997. Version PDF ici
[216] Eur J Cancer. 2003 Dec;39(18):2600-10. Cancer survival in European adolescents and young adults. Gatta G, Capocaccia R, De Angelis R, Stiller C, Coebergh JW; EUROCARE Working Group. Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori. http://pubmed.gov
[217] Lancet Oncol. 2006 Feb;7(2):132-40. Survival from rare cancer in adults: a population-based study. Gatta G, Ciccolallo L, Kunkler I, Capocaccia R, Berrino F, Coleman MP, De Angelis R, Faivre J, Lutz JM, Martinez C, Moller T, Sankila R; EUROCARE Working Group. Epidemiology Unit, National Cancer Institute, Milan, Italy. http://pubmed.gov
[218] Ai Zheng. 2005 Oct;24(10):1249-51. Feasibility of thoracoscopic pulmonary metastasectomy. Yang P, Yang LH, Gu LJ, Wang JY. Department of Cardiothoracic Surgery, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. http://pubmed.gov
[219] Zhonghua Wai Ke Za Zhi. 2003 Feb;41(2):116-8. Clinical analysis of 251 cases of soft tissue sarcomas. Shi YQ, Zong XY, Wang J, Li S. Department of Abdominal Oncological Surgery, Cancer Hospital, Fudan University, Shanghai. http://pubmed.gov
[220] Société Française de Psychologie
[221] Psychothérapie vigilance.com
[222] http://www.doctissimo.fr/html/sante/encyclopedie/sa_1012_psychanalyse.htm
[223] J Clin Oncol. 2002 Nov 1;20(21):4344-52. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables.Stojadinovic A, Leung DH, Allen P, Lewis JJ, Jaques DP, Brennan MF.http://pubmed.gov
[224] Am J Clin Oncol. 2006 Feb;29(1):62-5. Adjuvant radiotherapy in the management of soft tissue sarcoma involving the distal extremities. Schoenfeld GS, Morris CG, Scarborough MT, Zlotecki RA. Department of Radiation Oncology, University of Florida College of Medicine. http://pubmed.gov
[225] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):852-9. Results of radiation therapy for unresected soft-tissue sarcomas. Kepka L, DeLaney TF, Suit HD, Goldberg SI. http://pubmed.gov
[226] Mark C. Gebhardt, MD. Frederick W. and Jane M. Ilfield Professor of Orthopedic Surgery Harvard Medical School Children's Hospital, Boston Chief of the Department of Orthopedic Surgery Orthopaedic Surgeon-in-Chief Beth Israel Deaconess Medical Center and Peter J. Buecker, MD Fellow, Orthopaedic Oncology Harvard Combined Orthopaedic Surgery Boston, MA. http://www.liddyshriversarcomainitiative.org
[227] Andrea Ferrari MD Pediatric Oncology unit and Paola Collini MD Pathology Department, Istituto Nazionale per lo studio e la Cura dei Tumori, Milano MI, Italy. http://www.liddyshriversarcomainitiative.org
[228] http://www.liddyshriversarcomainitiative.org
[229] Leonard H. Wexler, MD Head, Soft Tissue Sarcoma Section Associate Member Department of Pediatrics Memorial Sloan-Kettering Cancer Center New York, NY http://www.liddyshriversarcomainitiative.org
[230] John M. Goldberg, MD and Karen Albritton, MD. Dana-Farber Cancer Institute Children’s Hospital, Boston http://www.liddyshriversarcomainitiative.org
[231] James M. Lewis, MD. Fellow, Surgical Oncology H. Lee Moffitt Cancer Center & Research Institute, Vernon K. Sondak, MD, FACS Chief, Division of Cutaneous Oncology Director of Surgical Education H. Lee Moffitt Cancer Center & Research Institute. Professor, Departments of Interdisciplinary Oncology and Surgery University of South Florida College of Medicine. http://www.liddyshriversarcomainitiative.org
[232] Peter J. Buecker, MD Fellow, Orthopaedic Oncology Harvard Combined Orthopaedic Surgery Boston, MA Mark C. Gebhardt, MD Frederick W. and Jane M. Ilfield Professor of Orthopedic Surgery Harvard Medical School Children's Hospital, Boston Chief of the Department of Orthopedic Surgery Orthopaedic Surgeon-in-Chief Beth Israel Deaconess Medical Center and Kristy Weber, MD Associate Professor, Department of Orthopaedic Surgery and Oncology Chief, Division of Orthopaedic Oncology Johns Hopkins University Baltimore, MD. http://www.liddyshriversarcomainitiative.org
[233] . Lor Randall, MD, FACS Director, Sarcoma Services Chief, SARC Lab Huntsman Cancer Institute & Primary Children’s Medical Center University of Utah. http://www.liddyshriversarcomainitiative.org
[234] Académie Nationale de Chirurgie 2006 - Techniques innovantes en chirurgie thoracique oncologique. R Giudicelli, H Dutau. PDF ici.
[235] Recommandations pour la prise en charge de la douleur. Agence Nationale pour le Développement de l'Evaluation Medicale. Oct 1995. 
[236] Actualités dans le traitement des douleurs cancéreuses. Bull Cancer 2004;91(1):95-8. Synthèse John Libbey Euro Text. PDF ici.
[237] Tramadol on neuropathic pain. Minerva Anestesiol 2005;71:565-84. C. Mattia, F.Coluzzi. 
[238] Mechanisms of disease neuropathic pain. R. Baron. 27 Juillet 2005. Christian Albrechts Universität. Germany. PDF ici.
[239] New and emerging treatment options of neuropathic pain. B. Gidal, R. Billington. The American Journal of Managed Care. 2006, Vol 12. N°9. PDF ici.
[240] Neuropathic pain : a practical guide for the clinician. I. Gilron, C.Peter, N. Watson. Août 2006. Association Médicale Canadienne. Department of Neurology. PDF ici.
[241] Traitement des douleurs. Centre National Hospitalier d'Information sur le Médicament. 2000. 
[242] Standards, Options et recommandations pour l'évaluation de la douleur chez l'adulte et l'enfant atteints d'un cancer. Fédération Nationale des Centres de Lutte contre le cancer. 2003. 
[243] Pain. 1998 Feb;74(2-3):205-11. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain.Benedetti F, Vighetti S, Amanzio M, Casadio C, Oliaro A, Bergamasco B, Maggi G. http://pubmed.gov
[244] Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):399-409. Antidepressants in the treatment of neuropathic pain.Sindrup SH, Otto M, Finnerup NB, Jensen TS. http://pubmed.gov
[245] Cochrane Database Syst Rev. 2006 Jul 19;3:CD003726.  Tramadol for neuropathic pain.Hollingshead J, Duhmke RM, Cornblath DR. http://pubmed.gov
[246] Am Fam Physician. Cochrane Database. 2006 Jun 1;73(11):1933-4. Antidepressants for the treatment of neuropathic pain.Cayley WE Jr. http://pubmed.gov
[247] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005452. Gabapentin for acute and chronic pain.Wiffen PJ, McQuay HJ, Edwards JE, Moore RA. Pain Research Unit, Churchill Hospital, Old Road, Headington, Oxford. http://pubmed.gov
[248] Palliat Med. 2004 Jan;18(1):5-11.  Gabapentin in the treatment of neuropathic pain.Bennett MI, Simpson KH. St Gemma's Hospice, Leeds, UK. http://pubmed.gov
[249] Minerva Anestesiol. 2002 Mar;68(3):105-14. New antidepressants in the treatment of neuropathic pain. A review.Mattia C, Paoletti F, Coluzzi F, Boanelli A. Institute of Anaesthesiology and Intensive Care Medicine, University of Studies La Sapienza, Rome, Italy. http://pubmed.gov
[250] Curr Med Res Opin. 2004 Dec;20(12):1877-81.  Focus on levomepromazine.Green B, Pettit T, Faith L, Seaton K. Cheadle Royal Hospital, Department of Psychiatry, University of Liverpool, UK. http://pubmed.gov
[251] http://www.samu.asso.nc/Cours_douleur/Seminaire_4/PSYCHOTROPES%20%20et%20%20DOULEURS.htm
[251] Chest. 2004 . Is major pulmonary resection by video-assisted thoracic surgery a adequate pocedure in clinical stage I lung cancer ? Takashi Ohtsuka, Hiroaki Nomori, Hirotoshi Horio.  PDF ici.
[252] The Annals Of thoracic Surgery. 2001. Pulmonary Function, Postoperative pain, and Serum cytokine level after lobectomy : a comparison of VATS and conventional procedure. Itaru Nagahiro, Akio Andou, Motoi Aoe. PDF ici.
[253] Chest. 2002 Nov. Quality Of Life following lung cancer resection : VATS vs Thoracotomy. Wilson W. L. Li, T.W. Lee, Shirley S. Y. Lam.  PDF ici.
[254] European Journal Of Cardio-Thoracic Surgery. 2003. The Impact of thoracic surgical access on early shoulder function : video-assisted thoracic surgery ves posterolateral thoracotomy. Wilson W.L. Li, Rosanna L.M. Lee, T.W. Lee. PDF ici.
[255] Nippon Geka Gakkai Zasshi. 2006 Mar;107(2):69-72. Video-assisted thoracoscopic surgery for lung cancer: current indications. Kondo H.Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan. http://pubmed.gov
[256] Ann Surg. 2006 Sep;244(3):420-5.  Thoracoscopic lobectomy is a safe and versatile procedure: experience with 500 consecutive patients.Onaitis MW, Petersen RP, Balderson SS, Toloza E, Burfeind WR, Harpole DH Jr, D'Amico TA. Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. http://pubmed.gov
[257] Curr Opin Pulm Med. 2005 Jul;11(4):282-6.  New approaches to the minimally invasive treatment of lung cancer.McKenna RJ Jr, Houk WV. Center for Chest Diseases, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. http://pubmed.gov
[258] Radiology. June 2004. Thoracic Tumors Treated with CT-guided Radiofrequency Ablation : Initial Experience. PDF ici.
[259] J Vasc Interv Radiol. May 2004. Akeboshi & all. Percutaneous Radiofrequency Ablation of Lung Neoplasms : Initial Therapeutic Response. PDF ici. 
[260] Deutsch Arztebl 2006. Diagnosis and Treatments of Neuropathic Pain. Ralf Baron. PDF ici.
[261] Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42(14):2493-7.
[262] Pommier Y, Kohlagen G, Bailly C, Waring M, Mazumder A, Kohn K. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-13309.
[263] Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth G, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. European Journal of Cancer 2001;37:97-105.
[264] Garcia-Rocha M, Garcia-Gravalos MD, Avila J. Characterization of antimitotic products from marine organisms that disorganize the microtubule network: ecteinascidin 743, isohomohalichondrin-B and LL-15. Br J Cancer 1996;73(8):875-83.
[265] Takebayashi Y, Pourquier P, Yoshida A, Kohlhagen G, Pommier Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci U S A. 1999;96:7196-7201.
[266] Bonfanti M, La Valle E, Fernandez Sousa Faro JM, Faircloth G, Caretti G, Mantovani R, et al. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999;14(3):179-86.
[267] Jin S, Gorfajn B, Faircloth G, Scotto K. Ecteinascidin 743, a transcription targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A. 2000;97:6775-6779.
[268] Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, et al. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to ecteinascidin-743 (ET-743). Br J Cancer 2000;82:1732-1739.
[269] Kanzaki A, Takebayashi Y, Ren X-Q, Miyashita H, Mori S, Akiyama S-I, et al. Overcoming multi drug resistance in p-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743. 2002.
[270] Puchalski T, Ryan D, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-hr. continuous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002;50:309-309.
[271] Li W, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff Y, Jimeno J, et al. Sensititvity of soft tissue sarcoma cell lines to chemotherapeutic agents: indication of ecteinascidin-743 as a potent cytotoxic agent. Clinical Cancer Res 2001;7:2908-2911.
[272] Scotlandi K, Perdichizzi S, Manara M, Serra M, Benini S, Cerisano V, et al. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clinical Cancer Res 2002;8:3893-3903.
[273] Takahashi N, Li W, Banerjee D, Scotto K, Bertino J. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clinical Cancer Res 2001;7:3251-3257.
[274] Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan M, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002;62:6909-6915.
[275] Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi R, et al. Effective combination of Et-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003;52:131-138.
[276] D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. European Journal of Cancer 2003;39:1920-1926.
[277] Morioka H, Weissbach L, Vogel T, Nielsen G, Faircloth G, Shao L, et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clinical Cancer Res 2003;9:1211-1217.
[278] Taamma A, Misset J, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, et al. Phase I and pharmacokinetic study of Ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-1265.
[279] Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymon E, et al. Ectinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients- preliminary evidence of activity. J Clin Oncol 2001;19:1248-1255.
[280] Ryan D, Supko J, Eder J, Seiden M, Demetri G, Lynch T, et al. Phase I and Pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous infusion in patients with solid malignancies. Clinical Cancer Res 2001;7:231-242.
[281] van Kesteren C, Twelves C, Bowman A, Hoekman K, Lopez-Lazaro L, Jimeno J, et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs. 2002;13:381-393.
[282] Villalona-Calero M, Eckhardt S, Weiss G, Hildago M, Beijnen J, van Kesteren C, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clinical Cancer Res 2002;8:75-85.
[283] Gomez J, Lopez Lazaro L, Guzman C, Gonzalez A, Misset J, Twelves C, et al. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. In: American Society of Clinical Oncology; 2000; New Orleans, LA; 2000. p. 187a. [284] Donald S, Verschoyle R, Greaves P, Gant T, Colombo T, Zucchetti M, et al. Complete protection by high dose dexamethasone against the hepatotoxicity of the novel antitumor drug ecteinascidin-743 (ET-743) in the rat. Cancer Res 2003;63:5902-5908.
[285] Demetri GD. ET-743: The US experience in sarcomas of the soft tissues. Anti-Cancer Drugs 2002;13:S7-S9.
[286] Garcia-Carbonero R, Supko J, Manola J, Seiden M, Harmon D, Ryan D, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490.
[287] Yovine A, Riofrio M, Blay J, Brain E, Alexandre J, Kahatt C, et al. Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-900. [288] Laverdiere C, Kolb E, Supko J, Gorlick R, Meyers P, Maki R, et al. Phase II study of Ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-840. Z
[288] Fédération Nationale des centres de lutte contre le cancer (FNLCC). Standards, Options et Recommandations pour la prise en charge des patients adultes atteints de sarcome des tissus mous. Mars 2006. Télécharger gratuitement l'intégralité en PDF ici.
[289] Fédération Nationale des centres de lutte contre le cancer (FNLCC). Standards, Options et Recommandations pour l’utilisation de la tomographie par émission de positons au [18F]-FDG (TEP-FDG) en cancérologie. Nov 2003. Télécharger gratuitement l'intégralité en PDF ici 

Retour au menu principal